- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06367322
Statins and Post-ERCP Acute Pancreatitis (Stark Project) (Stark)
Stark Project: Statins and Risk of Post-Endoscopic Retrograde Cholangiopancreatography Acute Pancreatitits.
Study Overview
Detailed Description
Introduction:
Acute Pancreatitis (AP) is the most frequent complication after ERCP; its incidence is around 3.5-4.5%. Post-ERCP AP (PEAP) is defined as a clinical pancreatitis (new or worsened abdominal pain) with amylase/lipase at least three times the upper limit of normal at more than 24 hours after the procedure, requiring hospital admission or a prolongation of planned admission. It is resulting in increased morbidity of patients undergoing this technique, and an increased in health spending, due to prolonged hospital days and patient needs. In this context, different strategies have been investigated to prevent PEAP, for example rectal NSAIDs (indomethacin or diclofenac 100 mg just before or after procedure) and pancreatic stents.
On the other hand, statins are widely used drugs aimed to lower cholesterol blood levels (the frequency of statin use, may be as high as 50% of men and 36% of women between the ages of 65 years and 74 years in USA). The relationship between statins and AP has been controversial. In the past, it was believed that statins were associated to an increased risk of AP. In Data Sheet of different International Drug Agencies, we can find their mainly indications (hypercholesterolemia, mixed dyslipidaemias, hereditary hypercholesterolemia) and commons adverse effects with reference to acute pancreatitis (myopathy, rhabdomyolysis, hepatitis/jaundice, acute pancreatitis…). Besides, some studies, most of them case series or case reports, have associated the use of different statins with drugs induced AP.
However, recent evidence suggests the opposite: Statins could reduce the risk of AP. In a retrospective longitudinal cohort study on data from a big health database from California (USA), with a big population of three millions nine thousand people, the incidence of AP among subjects who used simvastatin was significantly lower than who didn´t use it (0,80 (0,80-0,81)/100.000 consumers/day versus 1,28 (1,27-1,28) /100.000 no consumers/day; crude incidence rate ratio for risk of AP with simvastatin use 0.626 (95% confidence interval (CI) 0.588-0.668, p<0.0001). In this study patients who received simvastatin were more likely to have gallstone-related disorders, alcohol dependence or hyper-triglyceridemia compared with the reference population; nevertheless, risk of AP was significantly reduced with simvastatin use. In multivariate analysis, simvastatin was independently associated with reduced risk of pancreatitis, adjusted RR 0.29 (95%CI 0.27-0.31) after adjusting for age, gender, race/ethnicity, gallstone disorders, alcohol dependence, smoking and hypertriglyceridemia. Similar results were noted with atorvastatin. In a Meta-analysis of 21 randomized controlled trials investigating effects of lipid-modifying therapies on cardiovascular events, was assessed the relationship between lipid modifying therapies and risk of AP. In this study it was concluded that the use of statin therapies was associated with a lower risk of AP, RR 0.79 (95%CI 0.65-0.95; p=0.01). In a case-control study from Denmark, it was examined if statins use is associated with increase risk of acute pancreatitis. 2576 first-time admitted cases of AP were controlled with 25 817 gender-matched controls from the general population. Prescriptions for statins prior to admission with acute pancreatitis or index date among controls were retrieved from prescription databases. Its findings speak against a strong causative effect of statins on the risk of acute pancreatitis, and speculated about it could indicate a mild protective effect.
Some studies even speculate about an improvement in the severity of AP among patients with prior use of statins. In a prospective cohort study from Croatia, which included patients with acute pancreatitis divided into two groups according to statin use prior to hospitalization, severe disease was more common in the no-statin group than in statin group (20.6% vs. 8.7% p=0.001), and severity markers were also higher in the no-statin group.
It isn´t clear what is the mechanism by which statins might have a beneficial effect on acute pancreatitis. Basic studies suggest that statins could act on a specific anti-inflammatory pathway, inhibited them, as hypothesize experimental models. Statin effect that may be relevant to AP include blockade of the interleukin 6 mediated Janus kinase/signal transducer pathway and up regulation of the unfolded protein response helpful in modulating the endoplasmic reticulum stress response.
Based on the above evidence, the study hypothesis is that statins consumption is associated to a decreased incidence of PEAP. A prospective cohort study is proposed, focused on patients undergoing ERCP, with the aim to compare the incidence of PEAP among patients consuming statins and those who do not.
Material and Methods:
Hypothesis: Statins consumption decreases incidence of PEAP. I. Main aim: Compare the incidence of PEAP among patients consuming statins and those who do not.
II. Secondary aims:
- Investigate the effect of other drugs, especially acetylsalicylic acid (ASA), in the incidence of PEAP.
- Study the statin mechanism to decrease the incidence of AP.
- Study the relationship between use of statins and the severity of AP.
Design Study: International multicentric cohort study (observational, analytical, prospective), focused on patients undergoing ERCP, with the aim to compare the incidence of PEAP among patients consuming statins (any statin) and those who do not.
Data acquisition:
Data were prospectively acquired by researchers from the participating centers. After informed consent, the patients were interviewed before and immediately after ERCP. According to local clinical practice, most of the patients were admitted for 24 hours after the procedure to monitor for possible post-ERCP complications, including PEAP. Patients discharged earlier were instructed to return in case of concerning symptoms (persistent abdominal pain, nausea, vomiting, fever, gastrointestinal bleeding etc.). Names and identification data of the patients were not recorded on the electronic case report form in order to ensure confidentiality in accordance with data protection laws. Data monitoring was performed by one of the collaborators. Demographic and analytical data, comorbidities, treatments received (more specifically statins and ASA), pancreatic diseases, procedure results and post-procedural complications were collected.
Sample calculation:
The sample size calculation was based on a presumed 5% incidence of PEAP among non-statin users, an expected 1:3 ratio of statin users to non-users, and a 70% decrease of PEAP rate among statin users. The alpha-error was set to 0.05 and beta-error was set to 0.20. A sample of 1016 patients was accordingly calculated.
Statistical analysis:
The results are expressed as the mean (standard deviation: SD), median (interquartile range: IQR), or n (%). Normality was assessed by means of the Shapiro-Wilk test. For bivariate analysis, quantitative variables were compared with qualitative variables by means of the Student t-test and Mann-Whitney U-test for 2 categories or with ANOVA/Kruskal-Wallis tests for more than 2 categories. Qualitative variables were compared with the chi-square test or Fisher's exact test if needed. Multivariate analysis was performed by means of binary logistic regression. Incidence, odds ratio (OR), and adjusted OR (aOR) were used as measures of the frequency and strength of association, and 95% confidence intervals (CIs) were calculated for OR and aOR. Both OR (95% CI) and aOR (95% CI) were calculated by means of binary logistic regression (bivariate and multivariate analysis, respectively). The multivariate model included those variables that reached statistical significance in the bivariate analysis (p < 0.05), those variables considered as definite risk factors of PEAP according to the 2014 ESGE guidelines [1], and the prophylactic measures such as periprocedural rectal administration of diclofenac or indomethacin or placement of a pancreatic stent. All statistical tests were 2-tailed, and p-values of less than 0.05 were considered statistically significant.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Alicante, Spain, 03010
- Hospital General Universitario de Alicante
-
Alicante, Spain, 03010
- Alicante
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients ≥ 18 years old scheduled for ERCP and willing to participate were included.
Exclusion Criteria:
- Patients with ongoing AP
- Surgically altered biliary anatomy (such as hepatico-jejunostomy or choledoco-duodenostomy)
- Failure to reach the papilla
- Patients undergoing ERCP for stent removal or exchange
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Statin users
Patients ≥ 18 years old scheduled for ERCP according to a medical indication, and willing to participate were included, who were receiving treatment with statins. Excluded: patients with ongoing AP, surgically altered biliary anatomy (such as hepatico-jejunostomy or choledoco-duodenostomy), or failure to reach the papilla as well as patients undergoing ERCP for stent removal or exchange were excluded. |
The primary objective of this study was to determine whether the use of statin has a protective effect against PEAP. Patients undergoing ERCP for a specific medical indication were prospectively reviewed and the incidence of PEAP was compared according to whether or not the patients were receiving statin therapy. |
Non-statin users
Patients ≥ 18 years old scheduled for ERCP according to a medical indication, and willing to participate were included, who were not receiving treatment with statins. Excluded: patients with ongoing AP, surgically altered biliary anatomy (such as hepatico-jejunostomy or choledoco-duodenostomy), or failure to reach the papilla as well as patients undergoing ERCP for stent removal or exchange were excluded. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the incidence and relative risk of PEAP according to statin use.
Time Frame: 2 years
|
The primary outcome was to compare the incidence and relative risk of PEAP between users of statins and non-users of statins.
Subgroup analysis included type of statin and dosing and the consumption of statins the night before the procedure.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the effect of chronic use of other drugs on the incidence and relative risk of PEAP.
Time Frame: 2 years
|
The secondary outcome was to investigate the effect of chronic use of other drugs, particularly ASA, on the incidence and relative risk of PEAP.
|
2 years
|
To assess the effect of other factors (demographic and endoscopic) on the incidence and relative risk of PEAP and severity of PEAP (severity according to the Revised Atlanta Classification).
Time Frame: 2 years
|
Other secondary outcome was to investigate the effect of other factors [body mass index (kg/m2), age (years), active smoking (yes/not), active alcoholism (yes/not), suspected Oddi's dysfunction (yes/not), female sex (yes/not), previous PA (yes/not), duration of cannulation attempts > 10 minutes (yes/not), pancreatic guide passages > 1 (yes/not), pancreatic injection (yes/not), and prophylactic endoscopic measures such as periprocedural rectal administration of diclofenac or indomethacin or placement of a pancreatic stent (yes/not)] on the incidence of PEAP, and the association between the use of statins and ASA and the severity of PEAP.
|
2 years
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Dumonceau JM, Andriulli A, Elmunzer BJ, Mariani A, Meister T, Deviere J, Marek T, Baron TH, Hassan C, Testoni PA, Kapral C; European Society of Gastrointestinal Endoscopy. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014. Endoscopy. 2014 Sep;46(9):799-815. doi: 10.1055/s-0034-1377875. Epub 2014 Aug 22.
- Wu BU, Pandol SJ, Liu IL. Simvastatin is associated with reduced risk of acute pancreatitis: findings from a regional integrated healthcare system. Gut. 2015 Jan;64(1):133-8. doi: 10.1136/gutjnl-2013-306564. Epub 2014 Apr 17.
- Anagnostopoulos GK, Tsiakos S, Margantinis G, Kostopoulos P, Arvanitidis D. Acute pancreatitis due to pravastatin therapy. JOP. 2003 May;4(3):129-32.
- Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB, LaRosa JC, DeMicco DA, Colhoun HM, Goldenberg I, Murphy MJ, MacDonald TM, Pedersen TR, Keech AC, Ridker PM, Kjekshus J, Sattar N, McMurray JJ. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA. 2012 Aug 22;308(8):804-11. doi: 10.1001/jama.2012.8439.
- Thisted H, Jacobsen J, Munk EM, Norgaard B, Friis S, McLaughlin JK, Sorensen HT, Johnsen SP. Statins and the risk of acute pancreatitis: a population-based case-control study. Aliment Pharmacol Ther. 2006 Jan 1;23(1):185-90. doi: 10.1111/j.1365-2036.2006.02728.x.
- Gornik I, Gasparovic V, Gubarev Vrdoljak N, Haxiu A, Vucelic B. Prior statin therapy is associated with milder course and better outcome in acute pancreatitis--a cohort study. Pancreatology. 2013 May-Jun;13(3):196-200. doi: 10.1016/j.pan.2013.03.008. Epub 2013 Mar 14.
- Wei L, Yamamoto M, Harada M, Otsuki M. Treatment with pravastatin attenuates progression of chronic pancreatitis in rat. Lab Invest. 2011 Jun;91(6):872-84. doi: 10.1038/labinvest.2011.41. Epub 2011 Mar 7.
- Almeida JL, Sampietre SN, Mendonca Coelho AM, Trindade Molan NA, Machado MC, Monteiro da Cunha JE, Jukemura J. Statin pretreatment in experimental acute pancreatitis. JOP. 2008 Jul 10;9(4):431-9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EMP-PARA-20170-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-ERCP Acute Pancreatitis
-
First People's Hospital of HangzhouCompletedPost-ERCP Pancreatitis | Pancreatitis, Acute NecrotizingChina
-
David Vitale MDRecruiting
-
Dartmouth-Hitchcock Medical CenterRecruiting
-
Radboud University Medical CenterRecruitingPost-ERCP Acute PancreatitisNetherlands
-
Johns Hopkins UniversityRecruitingRectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis (INTRO)Post-ERCP Acute PancreatitisUnited States, Singapore, India
-
University of South FloridaNot yet recruitingPost-ERCP Acute Pancreatitis
-
Erasme University HospitalCompletedPost-ERCP Acute PancreatitisTaiwan, Belgium
-
Air Force Military Medical University, ChinaUnknownPost-ERCP Acute PancreatitisChina
-
Johns Hopkins UniversityPostgraduate Institute of Medical Education and Research; Asian Institute of... and other collaboratorsCompletedPost-ERCP Acute PancreatitisIndia, United States
-
Technical University of MunichKU Leuven; Northern State University, Russia; Latvijas Universitates MedicinasCompletedPost-ERCP Acute PancreatitisBelgium, Germany, Latvia, Russian Federation
Clinical Trials on Statin
-
Organon and CoMerck Sharp & Dohme LLCCompletedHypercholesterolemia | Coronary Heart Disease | Hyperlipidemia
-
Antalya Training and Research HospitalCompleted
-
National Taiwan University HospitalCompletedOut-Of-Hospital Cardiac ArrestTaiwan
-
Faculty of Medicine, Tarumanagara UniversityCengkareng General HospitalCompletedAcute Coronary Syndrome | Cardiogenic Shock | Recurrent Myocardial InfarctionIndonesia
-
Taipei Medical University WanFang HospitalTerminated
-
University of Sao Paulo General HospitalUnknownAneurysmal Subarachnoid HemorrhageBrazil
-
Radboud University Medical CenterErasmus Medical Center; Academisch Medisch Centrum - Universiteit van Amsterdam...Completed
-
Translational Research Center for Medical Innovation...National Cerebral and Cardiovascular Center; Ministry of Health, Labour and... and other collaboratorsCompleted
-
National Taiwan University HospitalUnknown
-
Capital Medical UniversityRecruitingIntracerebral Hemorrhage | StatinsChina